Systems and methods for controlling inflammatory response
View Patent ↗A method and system for controlling inflammatory response at an internal tissue site of a patient utilizes a reduced-pressure treatment device. Controlling the inflammatory response may be accomplished in a number of ways that involve treating the inflammatory milieu. Treating the inflammatory milieu may include removing or moderating pro-inflammatory stimuli, e.g., fluids, enhancing perfusion of the tissue at or near the internal tissue site, or providing reduced-pressure therapy. The reduced-pressure treatment device is placed at or near the internal tissue site and is fluidly coupled to an external reduced-pressure source. The reduced-pressure treatment device provides reduced pressure proximate the tissue site and treats the inflammatory milieu. The reduced-pressure treatment device for controlling inflammatory response may be a minimally-invasive treatment device.
1. A method for controlling systemic inflammatory response in a patient, the method comprising the steps of:
deploying a reduced-pressure treatment device proximate an internal tissue site;
wherein the internal tissue site is in an abdominal cavity interior to the patient's peritoneum;
fluidly coupling an external reduced-pressure source to the reduced-pressure treatment device to provide reduced pressure proximate the internal tissue site;
providing reduced pressure from the external reduced-pressure source to the reduced-pressure treatment device;
treating a pro-inflammatory milieu at the internal tissue site to control systemic inflammatory response throughout the patient's body; and
wherein the step of treating a pro-inflammatory milieu comprises removing pro-inflammatory stimuli proximate the internal tissue site.
2. The method for controlling systemic inflammatory response of claim 1 ,
wherein the reduced-pressure treatment device comprises a minimally-invasive treatment device;
wherein the step of fluidly coupling an external reduced-pressure source to the reduced-pressure treatment device comprises fluidly coupling a reduced-pressure delivery conduit to the minimally-invasive treatment device and to the external reduced-pressure source; and
further comprising the step of removing the minimally-invasive treatment device from the abdominal cavity through a device incision.
3. The method for controlling systemic inflammatory response of claim 1 , further comprising the step of determining an intra-abdomen pressure using a pressure transducer associated with the reduced-pressure treatment device.
4. The method for controlling systemic inflammatory response of claim 1 , wherein the step of deploying a reduced-pressure treatment device comprises deploying the reduced-pressure treatment device at least partially into a paracolic gutter of the patient.
5. The method for controlling systemic inflammatory response of claim 1 , wherein the step of providing reduced pressure from the external reduced-pressure source to the reduced-pressure treatment device comprises providing reduced pressure for at least a time (t) >0.5 hours.
6. The method for controlling systemic inflammatory response of claim 1 , wherein the step of providing reduced pressure from the external reduced-pressure source to the reduced-pressure treatment device comprises providing reduced pressure for at least a time (t) >2.0 hours.
7. The method for controlling systemic inflammatory response of claim 1 , wherein the step of providing reduced pressure from the external reduced-pressure source to the reduced-pressure treatment device comprises providing reduced pressure for at least a time (t) >20.0 hours.
8. The method for controlling systemic inflammatory response of claim 1 , wherein the reduced-pressure treatment device comprises:
a plurality of encapsulated leg members, each encapsulated leg member having an interior portion with a leg manifold member and formed with fenestrations operable to allow fluid flow into the interior portion; and
a central connection member, wherein the central connection member has a connection manifold member and wherein each leg manifold member is in fluid communication with the connection manifold member, the central connection member having a first side and a second, tissue-facing side.
9. The method for controlling systemic inflammatory response of claim 8 , further comprising a connecting interface coupled to the central connection member.
10. The method for controlling systemic inflammatory response of claim 8 , wherein each encapsulated leg member of the plurality of encapsulated leg members comprises:
a first leg encapsulating member;
a second leg encapsulating member formed with fenestrations;
wherein the leg manifold member has a first side, a second, tissue-facing side, a first lateral edge, and a second lateral edge; and
wherein the first leg encapsulating member is disposed proximate the first side of the leg manifold member, the second leg encapsulating member is disposed proximate the second, tissue-facing side of the leg manifold member, and the first leg encapsulating member and the second leg encapsulating member are coupled proximate the first lateral edge and the second lateral edge of the leg manifold member.
11. The method for controlling systemic inflammatory response of claim 1 , wherein the reduced-pressure treatment device comprises:
an encapsulated leg member, the encapsulated leg member having a leg manifold member, an encapsulating envelope formed with fenestrations and enveloping the leg manifold member, and wherein the encapsulated leg member has an aspect ratio greater than 3.0; and
a connecting interface coupled to the encapsulated leg member and fluidly coupled to the leg manifold member.
12. The method for controlling systemic inflammatory response of claim 1 , wherein the reduced-pressure treatment device comprises:
an encapsulated leg member, the encapsulated leg member having a leg manifold member, an encapsulating envelope formed with fenestrations and enveloping the leg manifold member, and wherein the encapsulated leg member has an aspect ratio greater than 4.0; and
a connecting interface coupled to the encapsulated leg member and fluidly coupled to the leg manifold member.
13. The method for controlling systemic inflammatory response of claim 1 , wherein the reduced-pressure treatment device comprises:
an encapsulated leg member, the encapsulated leg member having a leg manifold member, an encapsulating envelope formed with fenestrations and enveloping the leg manifold member, and wherein the encapsulated leg member has an aspect ratio greater than 5.0; and
a connecting interface coupled to the encapsulated leg member and fluidly coupled to the leg manifold member.
14. The method for controlling systemic inflammatory response of claim 1 , wherein the reduced-pressure treatment device comprises:
a first leg manifold member;
a second leg manifold member, wherein the first leg manifold member and the second leg manifold member intersect to from a central connection site;
an encapsulating envelope forming an exterior layer over the first leg manifold member, the second leg manifold member, and the central connection site, and wherein the encapsulating envelope is formed with fenestrations to allow fluid flow into an interior portion.
15. The method for controlling systemic inflammatory response of claim 14 , wherein the first leg manifold member and the second leg manifold member form two obtuse angles and two acute angles.
16. The method for controlling systemic inflammatory response of claim 1 , wherein the reduced-pressure treatment device comprises:
a plurality of encapsulated leg members, each having an interior portion with a leg manifold member and formed with fenestrations operable to allow fluid flow into the interior portion, and each having a first end and a second end;
wherein each of the plurality of encapsulated leg members has a connecting interface on the first end;
a plurality of connecting conduits, each having a first end and a second end;
an interface conduit having a first end and second end;
wherein the first end of each of the plurality of connecting conduits is coupled to the second end of the interface conduit; and
wherein the second end of each of the plurality of connecting conduits is coupled to the plurality of encapsulated leg members at the connecting interface.